IMUX - Immunic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/2016
Total Revenue--6
Cost of Revenue--0.206
Gross Profit--5.794
Operating Expenses
Research Development9,5958,753787.562
Selling General and Administrative2,4021,252498.499
Non Recurring---
Others--30.89
Total Operating Expenses11,99710,0051,317.157
Operating Income or Loss-11,997-10,005-1,311.157
Income from Continuing Operations
Total Other Income/Expenses Net45543-
Earnings Before Interest and Taxes-11,997-10,005-1,311.157
Interest Expense-1-4-4
Income Before Tax-11,542-9,962-1,311.157
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-11,542-9,962-1,311.157
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-11,542-9,962-1,311.157
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-11,542-9,962-1,311.157